Mazyar Shadman, MD, on Evaluating MB-106 in a Multicenter Study
The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.
“The numbers are small and follow up is short. But we're very pleased to see the same trend of both efficacy and safety with this product that is now being manufactured in an industry-level facility. We have a study with manufacturing that took place at that Fred Hutch, but we're not seeing any differences [between the products]. And in fact, we're seeing improved T cell expansion... and we're continuing to enroll patients.”
Mustang Bio’s MB-106 third generation CD20-targeting chimeric antigen receptor (CAR) T-cell therapy yielded responses with a number of complete responses (CRs) and displayed CAR-T persistence in 3 patients with relapsed/refractory indolent non-Hodgkin lymphomas successfully treated (1 received non-conforming material) in the phase 1/2 multicenter clinical trial (NCT05360238).
The new data on MB-106 were presented by Mazyar Shadman, MD, MPH, associate professor, clinical research division, and attending physician, hematologic malignancies, Fred Hutch Cancer Center, and associate professor, medical oncology division, University of Washington School of Medicine, at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California.
Participants had favorable safety profiles with no cases of Grade 3 or Grade 4 cytokine release syndrome and no cases of immune effector cell-associated neurotoxicity syndrome. Two patients with follicular lymphoma had CRs and 1 with Waldenström macroglobulinemia had a very good partial response. Dosing is ongoing in the final dosing level (1.0×107 cells/kg).
CGTLive spoke with Shadman to learn more about new data and how the therapy demonstrated comparability between the product manufactured at the new facility and that originally produced at Fred Hutch for a single center study.
Click here to read more coverage of ASH 2023.
